Stem Cell Therapy for Multiple Sclerosis – A Pipeline Analysis report

◆상품코드 : IRTNTR20309
◆발행일 : 2018년 2월
◆페이지수 : 72
◆보고서 형식 : PDF / 영문
◆납품 방식 : Email
◆조사대상 지역 : 글로벌
◆산업분야 : 미분류
◆발행회사(조사회사) : Technavio
◆판매회사 : H&I글로벌리서치(주)
◆판매가격 옵션
Single User¥378,000 -> 환산 ₩3,780,000견적의뢰/구매/질문FORM
Five User¥432,000 -> 환산 ₩4,320,000견적의뢰/구매/질문FORM
Enterprise License¥540,000 -> 환산 ₩5,400,000견적의뢰/구매/질문FORM
※지불하실 금액은 상기금액이며, 세금 및 배송료는 없습니다.
※지불은 선불결제 방식이며, 신용카드결제 또는 계좌입금(국내/해외)이 선택가능합니다.
※구매의사를 FORM기입 또는 E메일로 연락주시면 담당자가 회신 드리겠습니다.
※배송은 입금 확인 후, E메일로 납품드리며, 일반적으로 당일~2일정도 소요됩니다.
※가격옵션 설명 : (Single User : 귀사내에서 1명만 사용가능 / Five User, Multi User : 귀사내에서 5명까지 사용가능 / Site License, Corporate License : 동일국내에서 인원제한없이 사용가능 / Global Site License, Enterprise License : 지역상관없이 인원제한없이 사용/공유 가능한 라이센스). 자세한 설명은 이용안내 페이지를 참고하세요.


[조사보고서 개요]

This pipeline analysis report offers detailed insights into the clinical trials landscape of the stem cell therapy for multiple sclerosis including molecules at different development stages. Moreover, the report also offers information about the therapeutic assessment of the pipeline molecules based on various segmentations including route of administration.
Key questions answered in the report include
• What are the stem cell molecules in the various development stages for multiple sclerosis?
• What are the companies that are currently involved in the development of stem cell therapy molecules for multiple sclerosis?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule.

[조사보고서 목차]

Table of Contents
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: STEM CELL THERAPY FOR MULTIPLE SCLEROSIS: AN INSIGHT
• Introduction

PART 05: MAJOR REGULATORY AUTHORITIES
• US
• Europe
• Japan
• Australia
• China

PART 06: PIPELINE LANDSCAPE

PART 07: COMPARATIVE ANALYSIS
• Mid-stage molecules (Phase I/II), 2017
• Early-stage molecule (Phase I), 2017
• Pre-clinical and discovery stage molecules, 2017
• Inactive (status unknown and terminated) molecules, 2017

PART 08: INDICATION ANALYSIS

PART 09: THERAPEUTIC ASSESSMENT BY ROA

PART 10: KEY COMPANIES
• Active companies: Category and parameters

PART 11: APPENDIX
• List of abbreviations
Exhibit 01: Drug approval process by US FDA
Exhibit 02: Pipeline landscape
Exhibit 03: Pipeline molecules in different developmental stages 2017
Exhibit 04: Overview: Human umbilical cord mesenchymal stem cells
Exhibit 05: Clinical trials description of Huma umbilical cord mesenchymal stem cells
Exhibit 06: Overview: Autologous adipose-derived mesenchymal cells
Exhibit 07: Clinical trials description of Autologous adipose-derived mesenchymal cells
Exhibit 08: Overview: PDA-001
Exhibit 09: Clinical trials description of PDA-001
Exhibit 10: Overview: MultiStem
Exhibit 11: Overview: MSC-NTF
Exhibit 12: Overview: AST-OPC1
Exhibit 13: Overview: NSI-777
Exhibit 14: Overview: ALLOCETRA
Exhibit 15: Overview: NeurArrest
Exhibit 16: Overview: Adult stem cell therapy
Exhibit 17: Overview: Umbilical cord-derived mesenchymal stem cells
Exhibit 18: Clinical trials description of Umbilical cord-derived mesenchymal stem cells
Exhibit 19: Overview: Autologous bone marrow-derived mononuclear stem cells
Exhibit 20: Clinical trials description of Autologous bone marrow-derived mononuclear stem cells
Exhibit 21: Pipeline molecules as per types of multiple sclerosis
Exhibit 22: Assessment by RoA
Exhibit 23: Active companies: Category and parameters 2017
Exhibit 24: Segmentation of companies 2017
Exhibit 25: Overview: American CryoStem 2017
Exhibit 26: Overview: Asterias Biotherapeutics 2017
Exhibit 27: Overview: Athersys 2017
Exhibit 28: Overview: Brainstorm Cell Therapeutics 2017
Exhibit 29: Overview: Celgene Cellular Therapeutics 2017
Exhibit 30: Overview: Cell Cure Neurosciences 2017
Exhibit 31: Overview: DaVinci Biosciences 2017
Exhibit 32: Overview: Enlivex Therapeutics 2017
Exhibit 33: Overview: Neuralstem 2017
Exhibit 34: Overview: Translational Biosciences 2017



[보고서에 포함된 내용]
세계시장규모, 세그멘트별 시장규모, 시장동향, 시장예측, 관련 기업정보 등

[면책사항]
http://www.globalresearch.kr/disclaimer

★조사보고서 [Stem Cell Therapy for Multiple Sclerosis – A Pipeline Analysis report]에 관해서 E메일 문의 연락
◆H&I글로벌리서치의 고객기업(예)◆